Bioavailability Assessment of Dapagliflozin in a Bioequivalence Study

The primary objective of this study is to evaluate the **bioavailability** of Dapagliflozin. This is a bioequivalence study, which is crucial for determining the rate and extent to which the active ingredient or active moiety is absorbed and becomes available at the site of action. Understanding the bioavailability of Dapagliflozin is clinically relevant as it ensures therapeutic efficacy and safety in patients requiring this medication. There are no secondary objectives listed for this study.

The clinical trial involves a **bioequivalence study** with a study population that includes both male and female participants. The age range of the participants falls within category code 3, which typically represents adults. The trial population includes a vulnerable population, although specific details regarding the total number of participants have not been provided by the sponsor. The selection criteria for participants, including any lifestyle considerations such as diet, physical activity, or habits, have not been disclosed. The study does not focus on a specific medical condition, as it is a bioequivalence study, and no principal inclusion criteria have been specified.

The clinical trial is designed as a **bioequivalence study** to evaluate the bioavailability of Dapagliflozin. The trial is categorized under Phase 2 and is expected to commence recruitment on August 20, 2025, with an estimated completion date of September 18, 2025. The study will employ a randomized, double-blind, controlled design to ensure the reliability and validity of the results. Participants will be involved in the study for a duration that aligns with the trial's timeline, with specific involvement periods determined by the study protocol.

The sequence of study visits begins with an inclusion visit, also known as the screening visit, where potential participants are assessed for eligibility based on predefined criteria. This visit is crucial for ensuring that only suitable candidates are enrolled in the trial. Following the inclusion visit, participants will attend a series of follow-up visits, which are scheduled at regular intervals to monitor their health status and the effects of the investigational product. These visits are essential for collecting data on the primary and secondary endpoints of the study. The trial will conclude with an end-of-study visit, where final assessments are conducted to gather comprehensive data on the bioavailability of Dapagliflozin.

Participant involvement is expected to last until the end of the study, unless specific conditions necessitate early termination. Such conditions may include adverse events, non-compliance with the study protocol, or withdrawal of consent by the participant. The study is structured to ensure that all procedures are conducted in accordance with ethical guidelines and regulatory requirements, thereby safeguarding the well-being of participants throughout the trial duration.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the study may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments or their administration protocols. Information regarding the monitoring of participant compliance with the dosing schedules is also not available in the provided data.

The clinical trial is designed to assess efficacy in a Phase 2 study. The trial is scheduled to commence recruitment on August 20, 2025, with an estimated completion date of September 18, 2025. The specific parameters or endpoints used to evaluate efficacy, as well as the methods and schedule for measuring, collecting, and analyzing these parameters, are not detailed in the provided data. The trial will proceed according to the standard protocols for a Phase 2 study, focusing on the assessment of efficacy in the context of the investigational treatment. The trial will adhere to rigorous scientific and ethical standards to ensure the reliability and validity of the efficacy assessments.